CommercialCoverageLow impact
08.02.10b, Beremagene Geperpavec (Vyjuvek™)
Independence Blue Cross·Dermatology, Pediatrics, Wound Care·Pharmacy
Effective date
Dec 19, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross has updated their pharmacy policy for Beremagene Geperpavec (Vyjuvek™), a gene therapy treatment. This is a reissued policy that will become effective December 19, 2025, indicating changes to coverage criteria or prior authorization requirements for this specialized medication.
Action Required
By December 19, 2025: Billing and clinical teams should review the updated Beremagene Geperpavec (Vyjuvek™) policy at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for this gene therapy medication. Update any relevant protocols for patients requiring this treatment.